Randomized trial of an education and support intervention
to prevent readmission of patients with heart failure
H. M. Krumholz, J. Amatruda, G. L. Smith, J. A. Mattera, S. A. Roumanis, M. J. Radford,
P. Crombie, V. Vaccarino
One of the less frequently addressed issues in
the management of heart failure is the high
readmission rate to hospital after an initial
inpatient episode...
Long-term trends in the incidence of and survival
with heart failure
D. Levy, S. Kenchaiah, M. G. Larson, E. J. Benjamin, M. J. Kupka, K. K. Ho,
J. M. Murabito, R. S. Vasan
Over recent decades, there have been significant
advances in the treatment of hypertension,
historically the leading cause of heart
failure...
Differential gene expression and genomic patient stratification
following left ventricular assist device support
B. C. Blaxall, B. M. Tschannen-Moran, C. A. Milano, W. J. Koch
Donor organs required for heart transplantation
are in limited supply and for many patients
the wait for transplant surgery proves
too long, with fatal deterioration before organ
availability...
Clinical assessment identifies hemodynamic profiles
that predict outcomes in patients admitted with heart failure
A. Nohria, S. W. Tsang, J. C. Fang, E. F. Lewis, J. A. Jarcho, G. H. Mudge, L. W. Stevenson
Despite the introduction of many new therapies
for the treatment of chronic heart failure,
morbidity and mortality remain high...
Effect of enalapril on 12-year survival and life expectancy in
patients with left ventricular systolic dysfunction: a follow-up study
P. Jong, S. Yusuf, M. F. Rousseau, S. A. Ahn, S. I. Bangdiwala
This paper describes the long-term outcomes
of patients recruited into the Studies Of Left
Ventricular Dysfunction (SOLVD)...
Targeted anticytokine therapy in patients with chronic
heart failure: results of the Randomized Etanercept Worldwide
Evaluation (RENEWAL)
D. L. Mann, J. J. McMurray, M. Packer, K. Swedberg, J. S. Borer, W. S. Colucci, J. Dijan,
H. Drexler, A. Feldman, L. Kober, et al
Observation of elevated levels of tumor necrosis
factor (TNF) in heart failure led to investigations
into its possible role in the pathophysiology
of the condition...
CRegenerative capacity of the myocardium: implications
for treatment of heart failure
R. von Harsdorf, P. A. Poole-Wilson, R. Dietz
This review article describes in some depth novel
approaches to the management of heart failure
and discusses the rationale for, as well as
the limitations of, each treatment...
Do we understand who benefits from resynchronisation therapy?
O. A. Breithardt, P. Claus, G. R. Sutherland
Cardiac resynchronization therapy (CRT) is now
an accepted tool in the treatment of severe
left ventricular dysfunction...
Hypertrophic cardiomyopathy
P. Elliott, W. J. McKenna
Hypertrophic cardiomyopathy (HCM) was first
described in 1869...
A meta-analysis of the effects of treatment on left ventricular
mass in essential hypertension
A. U. Klingbeil, M. Schneider, P. Martus, F. H. Messerli, R. E. Schmieder
As mentioned in the preceding summary, one
of the major questions that has plagued
physicians involved in the treatment of hypertension
over the last 40 years, with the development
of various classes of antihypertensive
drug with different mechanisms of action, is whether any
drug class is superior to any other in terms of preventing
cardiovascular morbidity and mortality...
|
